{"id":3288,"date":"2009-12-07T06:32:36","date_gmt":"2009-12-07T11:32:36","guid":{"rendered":"http:\/\/asweetlife.org\/?p=3288"},"modified":"2015-12-28T08:12:08","modified_gmt":"2015-12-28T13:12:08","slug":"novo-nordisk-starts-phase-1-trial-with-oral-insulin","status":"publish","type":"post","link":"https:\/\/asweetlife.org\/?p=3288","title":{"rendered":"Novo Nordisk Starts Phase 1 Trial With Oral Insulin"},"content":{"rendered":"<p><a href=\"https:\/\/asweetlife.org\/wp-content\/uploads\/2010\/01\/Novo-Nordisk-Logo.png\" rel=\"mfp\"><img decoding=\"async\" class=\"alignleft size-full wp-image-29471 lazyload\" title=\"Novo Nordisk Logo\" src=\"data:image\/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==\" data-src=\"https:\/\/asweetlife.org\/wp-content\/uploads\/2010\/01\/Novo-Nordisk-Logo.png\" alt=\"\" width=\"215\" height=\"160\" \/><\/a>Novo Nordisk\u00a0announced today that it has initiated its first phase 1 clinical trial with an oral insulin analogue (NN1952). The aim of the trial, conducted in Germany, is to investigate the safety, tolerance, exposure of drug and effect of NN1952 oral insulin in healthy volunteers and people with type 1 and type 2 diabetes.<br \/> Results from the trial, which plans to enroll about 80 people, are expected to be reported in the first half of 2011.<\/p>\n<div>There are many challenges with the development and production of a reliable insulin formulation for oral use. They include avoiding enzymatic degradation in the gastrointestinal tract, overcoming poor spontaneous insulin permeability over the intestinal wall, limiting variability of absorption (caused, for example, by interaction with food), and producing insulin in sufficient scale cost &#8211; effectively.<\/div>\n<p>NN1952 has been designed to address some of the key challenges relating to oral insulin delivery. Furthermore, it utilizes the GIPET\u00ae formulation technology from Merrion Pharmaceuticals to facilitate insulin absorption from the gut.<br \/> In November 2008, Merrion entered into a development and license agreement to develop and commercialize oral formulations of Novo Nordisk&#8217;s proprietary insulin analogues, using Merrion&#8217;s proprietary GIPET\u00ae technology (Gastrointestinal Permeation Enhancement Technology).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Novo Nordisk announced today that it has initiated its first phase 1 clinical trial with an oral insulin analogue (NN1952). The aim of the trial, conducted in Germany, is to investigate the safety, tolerance, exposure of drug and effect of NN1952 oral insulin in healthy volunteers and people with type 1 and type 2 diabetes&#8230;<\/p>\n","protected":false},"author":131,"featured_media":29471,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","footnotes":""},"categories":[1441],"tags":[311],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v22.9 (Yoast SEO v22.9) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Novo Nordisk Starts Phase 1 Trial With Oral Insulin<\/title>\n<meta name=\"description\" content=\"Novo Nordisk announced today that it has initiated its first phase 1 clinical trial with an oral insulin analogue. The aim of the trial is to investigate the safety, tolerance, exposure of drug and effect of NN1952 oral insulin..\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/asweetlife.org\/?p=3288\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"ASweetLife Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/asweetlife.org\/?p=3288\",\"url\":\"https:\/\/asweetlife.org\/?p=3288\",\"name\":\"Novo Nordisk Starts Phase 1 Trial With Oral Insulin\",\"isPartOf\":{\"@id\":\"https:\/\/asweetlife.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/asweetlife.org\/?p=3288#primaryimage\"},\"image\":{\"@id\":\"https:\/\/asweetlife.org\/?p=3288#primaryimage\"},\"thumbnailUrl\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2010\/01\/Novo-Nordisk-Logo.png\",\"datePublished\":\"2009-12-07T11:32:36+00:00\",\"dateModified\":\"2015-12-28T13:12:08+00:00\",\"author\":{\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585\"},\"description\":\"Novo Nordisk announced today that it has initiated its first phase 1 clinical trial with an oral insulin analogue. The aim of the trial is to investigate the safety, tolerance, exposure of drug and effect of NN1952 oral insulin..\",\"breadcrumb\":{\"@id\":\"https:\/\/asweetlife.org\/?p=3288#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/asweetlife.org\/?p=3288\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/asweetlife.org\/?p=3288#primaryimage\",\"url\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2010\/01\/Novo-Nordisk-Logo.png\",\"contentUrl\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2010\/01\/Novo-Nordisk-Logo.png\",\"width\":215,\"height\":160,\"caption\":\"Novo Nordisk Logo\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/asweetlife.org\/?p=3288#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/asweetlife.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novo Nordisk Starts Phase 1 Trial With Oral Insulin\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/asweetlife.org\/#website\",\"url\":\"https:\/\/asweetlife.org\/\",\"name\":\"ASweetLife\",\"description\":\"The Diabetes Magazine\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/asweetlife.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585\",\"name\":\"ASweetLife Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g\",\"caption\":\"ASweetLife Team\"},\"url\":\"https:\/\/asweetlife.org\/?author=131\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novo Nordisk Starts Phase 1 Trial With Oral Insulin","description":"Novo Nordisk announced today that it has initiated its first phase 1 clinical trial with an oral insulin analogue. The aim of the trial is to investigate the safety, tolerance, exposure of drug and effect of NN1952 oral insulin..","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/asweetlife.org\/?p=3288","twitter_misc":{"Written by":"ASweetLife Team","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/asweetlife.org\/?p=3288","url":"https:\/\/asweetlife.org\/?p=3288","name":"Novo Nordisk Starts Phase 1 Trial With Oral Insulin","isPartOf":{"@id":"https:\/\/asweetlife.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/asweetlife.org\/?p=3288#primaryimage"},"image":{"@id":"https:\/\/asweetlife.org\/?p=3288#primaryimage"},"thumbnailUrl":"https:\/\/asweetlife.org\/wp-content\/uploads\/2010\/01\/Novo-Nordisk-Logo.png","datePublished":"2009-12-07T11:32:36+00:00","dateModified":"2015-12-28T13:12:08+00:00","author":{"@id":"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585"},"description":"Novo Nordisk announced today that it has initiated its first phase 1 clinical trial with an oral insulin analogue. The aim of the trial is to investigate the safety, tolerance, exposure of drug and effect of NN1952 oral insulin..","breadcrumb":{"@id":"https:\/\/asweetlife.org\/?p=3288#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/asweetlife.org\/?p=3288"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/asweetlife.org\/?p=3288#primaryimage","url":"https:\/\/asweetlife.org\/wp-content\/uploads\/2010\/01\/Novo-Nordisk-Logo.png","contentUrl":"https:\/\/asweetlife.org\/wp-content\/uploads\/2010\/01\/Novo-Nordisk-Logo.png","width":215,"height":160,"caption":"Novo Nordisk Logo"},{"@type":"BreadcrumbList","@id":"https:\/\/asweetlife.org\/?p=3288#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/asweetlife.org\/"},{"@type":"ListItem","position":2,"name":"Novo Nordisk Starts Phase 1 Trial With Oral Insulin"}]},{"@type":"WebSite","@id":"https:\/\/asweetlife.org\/#website","url":"https:\/\/asweetlife.org\/","name":"ASweetLife","description":"The Diabetes Magazine","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/asweetlife.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585","name":"ASweetLife Team","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/asweetlife.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g","caption":"ASweetLife Team"},"url":"https:\/\/asweetlife.org\/?author=131"}]}},"_links":{"self":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts\/3288"}],"collection":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/users\/131"}],"replies":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3288"}],"version-history":[{"count":0,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts\/3288\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/media\/29471"}],"wp:attachment":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3288"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3288"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3288"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}